Deciphering the Potential Role of Specialized Pro-Resolving Mediators in Obesity-Associated Metabolic Disorders

• Published in: International journal of molecular sciences Vol. 25; no. 17; p. 9598
• Main Authors: Kim, Nahyun, Shin, Ha Youn
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 04.09.2024
• Subjects: Atherosclerosis; Biosynthesis; Body fat; Diabetes; Diet; Fatty acids; Inflammation; Insulin resistance; Lipids; Liver; Metabolic disorders; Metabolites; Obesity; Roles; specialized pro-resolving mediators
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms25179598

Obesity-related metabolic disorders, including diabetes, non-alcoholic fatty liver disease (NAFLD), and cardiovascular disease, increasingly threaten global health. Uncontrolled inflammation is a key pathophysiological factor in many of these conditions. In the human body, inflammatory responses generate specialized pro-resolving mediators (SPMs), which are crucial for resolving inflammation and restoring tissue balance. SPMs derived from omega-3 polyunsaturated fatty acids (n-3 PUFAs) such as resolvins, protectins, and maresins hold promise in attenuating the chronic inflammatory diseases associated with lipid metabolism disorders. Recent research has highlighted the therapeutic potential of n-3 PUFA-derived metabolites in addressing these metabolic disorders. However, the understanding of the pharmacological aspects of SPMs, particularly in obesity-related metabolic disorders, remains limited. This review comprehensively summarizes recent advances in understanding the role of SPMs in resolving metabolic disorders, based on studies in animal models and humans. These studies indicate that SPMs have potential as therapeutic targets for combating obesity, as well as offering insights into their mechanisms of action.